Opium consumption is negatively associated with serum prostate-specific antigen (PSA), free PSA, and percentage of free PSA levels

Journal of Addiction Medicine

Volumn 7, Issue 1, 2013, Pages 58-65

  Safarinejad, Mohammad Reza ^a   Asgari, Seyyed Alaeddin ^b   Farshi, Alireza ^c   Iravani, Shahrokh ^d   Khoshdel, Alireza ^d   Shekarchi, Babak ^d  

^a Clinical Center for Urological Disease Diagnosis   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Addiction; Drugs; Measurement; Prostate; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD LEVEL; CANCER GRADING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; URINALYSIS;

AGED; BIOPSY; BODY MASS INDEX; DELAYED DIAGNOSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION ROUTES; HORMONES; HUMANS; IRAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; OPIOID-RELATED DISORDERS; OPIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SOCIOECONOMIC FACTORS; STATISTICS AS TOPIC; SUBSTANCE ABUSE DETECTION;

EID: 84877987233     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31827b72d9     Document Type: Article

References (28)

1. Açikgöz Ş , Can M, Doǧan SM, et al. Prostate specific antigen levels after acute myocardial infarction. Acta Biochim Pol 2011;58: 541-545.
2. Adams ML, Sewing B, Forman JB, et al. Opioid-induced suppression of rat testicular function. J Pharmacol Exp Ther 1993;266: 323-328.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision. Washington, DC:American Psychiatric Press; 2000.
4. Blank MS, Fabbri A, Catt KJ, et al. Inhibition of luteinizing hormone release by morphine and endogenous opiates in cultured pituitary cells. Endocrinology 1986;118: 2097-2101.
5. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 1984;247:F632.
6. Cicero TJ, Bell RD, Wiest WG, et al. Function of the male sex organs in heroin and methadone users. N Engl J Med 1975;292: 882-887.
7. Giri M, Kaufman JM. Opioidergic modulation of in vitro pulsatile gonadotropin-releasing hormone release from the isolated medial basal hypothalamus of the male guinea pig. Endocrinology 1994;135: 2137-2143.
8. Grubb RL, III, Black A, Izmirlian G, et al. PLCOProject Team Serumprostatespecific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009;18: 748-751.
9. Han JH, Choi NY, Bang SH, et al. Relationship between serum prostatespecific antigen levels and components of metabolic syndrome in healthy men. Urology 2008;72: 749-754.
10. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43: 1809-1818.
11. Hosseini SY, Safarinejad MR, Amini E, et al. Opium consumption and risk of bladder cancer: a case-control analysis. Urol Oncol 2010;28: 610-616.
12. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90.
13. Kalra PS, Sahu A, Kalra SP. Opiate-induced hypersensitivity to testosterone feedback: pituitary involvement. Endocrinology 1988;122: 997-1003.
14. Kampa M, Bakogeorgou E, Hatzoglou A, et al. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol 1997;335: 255-265.
15. Kampa M, Papakonstanti EA, Alexaki VI, et al. The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line. Exp Cell Res 2004;294: 434-445.
16. Kampa M, Papakonstanti EA, Hatzoglou A, et al. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. FASEB J 2002;16: 1429-1431.
17. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO Collaborative Study on Substitution Therapy of Opioid Dependence and HIV/AIDS, World Health Organization. Addiction 2008;103: 1484-1492.
18. Loeb S, Carter HB, Schaeffer EM, et al. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol 2009;182: 2646-2651.
19. Moshtaghi-Kashanian GR, Esmaeeli F, Dabiri S. Enhanced prolactin level in opium smokers. Addic Biol 2005;10: 345-349.
20. Noordzij MA, van Steenbrugge GJ, van der Kwast TH, et al. Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res 1995;22: 333-341.
21. Ozcan T, Bozlu M, Muslu N, et al. Elevation of the serum total and free prostate specific antigen levels after stent implantation in patients with coronary artery disease. Swiss Med Wkly 2009;139: 672-675.
22. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100: 851-858.
23. Rundle A, Neugut AI. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 2008;68: 373-380.
24. Safarinejad MR. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol 2006;17: 1166-1171.
25. Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 2005;8: 304-310.
26. Vetlugina TP, Ivanova SA, Bokhan NA, et al. Changes in immunological parameters in patients with opium abuse receiving ANAR therapy. Bull Exp Biol Med 135 Suppl 2003;7: 189-191.
27. Wallner LP, Morgenstern H, McGree ME, et al. The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study. Urology 2011;77: 137-141.
28. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-02. Am J Epidemiol 2006;164: 978-983.